Florida-based DBA Systems has received premarket approval from the Food and Drug Administration for its film mammogram review and analysis workstation, ImagClear Mammography Review System. The product line offers several different models. The main
Florida-based DBA Systems has received premarket approval from the Food and Drug Administration for its film mammogram review and analysis workstation, ImagClear Mammography Review System.
The product line offers several different models. The main modelsthe CV 6000, Tech 5000, and VS 500are ready and available for clinical use, said Glenn Turner, DBA Systems manager of medical research and development.
Company officials said they hope to bridge the gap between film-based and filmless technology with the ImagClear system.
The ImagClear uses hardware, software, and communications technology that allow a radiologist to apply digital imaging techniques to the viewing, manipulation, and communication of film mammograms. Image capture is accomplished through the ImagClear systems film digitizer, which provides a pixel resolution of 42 microns and a gray-scale range of 16 bits to produce a minimum 4K x 5K image matrix, which is adequate for even the highest quality mammography films.
The image viewing software ImagClear uses was specifically designed to meet the demanding requirements of mammography. Images from the ImagClear Film Digitizer can be organized into studies and sessions and the system creates online reports.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.